TY  - JOUR 
AU  - Bergua, Juan
AU  - Montesinos, Pau
AU  - Martínez-Cuadrón, David
AU  - Fernández-Abellán, Pascual
AU  - Serrano, Josefina
AU  - Sayas, María J
AU  - Prieto-Fernández, Julio
AU  - García, Raimundo
AU  - García-Huerta, Ana J.
AU  - Barrios, Manuel
AU  - Benavente, Celina
AU  - Pérez Encinas, Manuel Mateo
AU  - Simiele, Adriana
AU  - Rodríguez-Macías, Gabriela
AU  - Herrera-Puente, Pilar
AU  - Rodríguez-Veiga, Rebeca
AU  - Martínez-Sánchez, María Pilar
AU  - Amador Barciela, María Lourdes
AU  - Riaza-Grau, Rosalía
AU  - Sanz, Miguel A.
PY  - 2016
UR  - http://hdl.handle.net/20.500.11940/22502
AB  - [EN] The combination of fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor (FLAG-Ida) is widely used in relapsed/refractory acute myeloid leukaemia (AML). We retrospectively analysed the results of 259 adult AML patients...
LA  - eng
KW  - Hematopoietic Stem Cell Transplantation
KW  - Leukemia, Myeloid, Acute
KW  - Risk Assessment
KW  - Gemtuzumab
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cytarabine
KW  - Prognosis
KW  - Recurrence
KW  - Salvage Therapy
KW  - Idarubicin
KW  - Remission Induction
KW  - Survival Analysis
KW  - Survivorship
KW  - Granulocyte Colony-Stimulating Factor
KW  - Retrospective Studies
KW  - Purine Nucleosides
TI  - A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia
DO  - 10.1111/bjh.14107
T2  - British Journal of Haematology
M2  - 700
KW  - FLAG-Ida
KW  - CHUS
KW  - CHUP
VL  - 174
ER  -